bioAffinity receives Nasdaq delisting notice; July CyPath Lung sales up 72% over prior monthly average

bioAffinity Technologies, Inc.

Nasdaq notified Company on Aug 7 that it failed to regain minimum bid price by Aug 6 and is ineligible for second 180-day period.
Stockholders' equity of $1,439,404 at March 31, 2025 remains below the $2.5M minimum, adding a second delisting basis.
Company intends to appeal by Aug 14, 2025; delisting scheduled for Aug 18 if appeal not filed.
July completed tests for CyPath Lung surged 72% over the average of the first six months of 2025.
Company reaffirms forecast of 3X year-over-year revenue for CyPath Lung; back-to-back record months in June and July.

item 3.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.